Top

Breast Cancer Research and Treatment

Published in:

01-06-2018 | Preclinical study

Systematical analysis of lncRNA–mRNA competing endogenous RNA network in breast cancer subtypes

Authors: Shunheng Zhou, Lihong Wang, Qian Yang, Haizhou Liu, Qianqian Meng, Leiming Jiang, Shuyuan Wang, Wei Jiang

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Abstract

Background

Breast cancer is one of the most common solid tumors in women involving multiple subtypes. However, the mechanism for subtypes of breast cancer is still complicated and unclear. Recently, several studies indicated that long non-coding RNAs (lncRNAs) could act as sponges to compete miRNAs with mRNAs, participating in various biological processes.

Methods

We concentrated on the competing interactions between lncRNAs and mRNAs in four subtypes of breast cancer (basal-like, HER2+, luminal A and luminal B), and analyzed the impacts of competing endogenous RNAs (ceRNAs) on each subtype systematically. We constructed four breast cancer subtype-related lncRNA–mRNA ceRNA networks by integrating the miRNA target information and the expression data of lncRNAs, miRNAs and mRNAs.

Results

We constructed the ceRNA network for each breast cancer subtype. Functional analysis revealed that the subtype-related ceRNA networks were enriched in cancer-related pathways in KEGG, such as pathways in cancer, miRNAs in cancer, and PI3k–Akt signaling pathway. In addition, we found three common lncRNAs across the four subtype-related ceRNA networks, NEAT1, OPI5-AS1 and AC008124.1, which played specific roles in each subtype through competing with diverse mRNAs. Finally, the potential drugs for treatment of basal-like subtype could be predicted through reversing the differentially expressed lncRNA in the ceRNA network.

Conclusion

This study provided a novel perspective of lncRNA-involved ceRNA network to dissect the molecular mechanism for breast cancer.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Munirah MA, Siti-Aishah MA, Reena MZ, Sharifah NA, Rohaizak M, Norlia A, Rafie MK, Asmiati A, Hisham A, Fuad I, Shahrun NS, Das S (2011) Identification of different subtypes of breast cancer using tissue microarray. Rom J Morphol Embryol 52(2):669–677PubMed

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5(10):2929–2943PubMedPubMedCentral

Heimes AS, Madjar K, Edlund K, Battista MJ, Almstedt K, Elger T, Krajnak S, Rahnenfuhrer J, Brenner W, Hasenburg A, Hengstler JG, Schmidt M (2017) Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer. Breast Cancer Res Treat 165(2):293–300. https://doi.org/10.1007/s10549-017-4327-0 CrossRefPubMed

Nie L, Wu HJ, Hsu JM, Chang SS, Labaff AM, Li CW, Wang Y, Hsu JL, Hung MC (2012) Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res 4(2):127–150PubMedPubMedCentral

Wang J, Ye C, Xiong H, Shen Y, Lu Y, Zhou J, Wang L (2016) Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication. Oncotarget. https://doi.org/10.18632/oncotarget.12537

Ning S, Zhang J, Wang P, Zhi H, Wang J, Liu Y, Gao Y, Guo M, Yue M, Wang L, Li X (2016) Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers. Nucleic Acids Res 44(D1):D980–D985. https://doi.org/10.1093/nar/gkv1094 CrossRefPubMed

Wang J, Ma R, Ma W, Chen J, Yang J, Xi Y, Cui Q (2016) LncDisease: a sequence based bioinformatics tool for predicting lncRNA-disease associations. Nucleic Acids Res 44(9):e90. https://doi.org/10.1093/nar/gkw093 CrossRefPubMedPubMedCentral

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146(3):353–358. https://doi.org/10.1016/j.cell.2011.07.014 CrossRefPubMedPubMedCentral

10.

Wang Y, Hou J, He D, Sun M, Zhang P, Yu Y, Chen Y (2016) The emerging function and mechanism of ceRNAs in cancer. Trends Genet 32(4):211–224. https://doi.org/10.1016/j.tig.2016.02.001 CrossRefPubMedPubMedCentral

11.

Sandhu R, Rein J, D’Arcy M, Herschkowitz JI, Hoadley KA, Troester MA (2014) Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. Carcinogenesis 35(11):2567–2575. https://doi.org/10.1093/carcin/bgu175 CrossRefPubMedPubMedCentral

12.

Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W (2015) ceRNA in cancer: possible functions and clinical implications. J Med Genet 52(10):710–718. https://doi.org/10.1136/jmedgenet-2015-103334 CrossRefPubMed

13.

Cheng DL, Xiang YY, Ji LJ, Lu XJ (2015) Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives. Tumour Biol 36(2):479–488. https://doi.org/10.1007/s13277-015-3093-z CrossRefPubMed

14.

Cancer Genome Atlas Research N (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519–525. https://doi.org/10.1038/nature11404 CrossRef

15.

Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, Weinstein JN, Liang H (2015) TANRIC: an interactive open platform to explore the function of lncRNAs in cancer. Cancer Res 75(18):3728–3737. https://doi.org/10.1158/0008-5472.CAN-15-0273 CrossRefPubMedPubMedCentral

16.

Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20(4):628–635. https://doi.org/10.1093/annonc/mdn675 CrossRefPubMed

17.

Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, Leopold V, Tay Y, Provero P, Zecchina R, Pandolfi PP (2013) Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci USA 110(18):7154–7159. https://doi.org/10.1073/pnas.1222509110 CrossRefPubMedPubMedCentral

18.

Liu D, Yu X, Wang S, Dai E, Jiang L, Wang J, Yang Q, Yang F, Zhou S, Jiang W (2016) The gain and loss of long noncoding RNA associated-competing endogenous RNAs in prostate cancer. Oncotarget. https://doi.org/10.18632/oncotarget.11128

19.

Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, Tsai TR, Ho SY, Jian TY, Wu HY, Chen PR, Lin NC, Huang HT, Yang TL, Pai CY, Tai CS, Chen WL, Huang CY, Liu CC, Weng SL, Liao KW, Hsu WL, Huang HD (2016) miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44(D1):D239–D247. https://doi.org/10.1093/nar/gkv1258 CrossRefPubMed

20.

Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P, Floros E, Dalamagas T, Hatzigeorgiou AG (2016) DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res 44(D1):D231–D238. https://doi.org/10.1093/nar/gkv1270 CrossRefPubMed

21.

Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, Califano A (2011) An extensive microRNA-mediated network of RNA–RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147(2):370–381. https://doi.org/10.1016/j.cell.2011.09.041 CrossRefPubMedPubMedCentral

22.

Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19(9):1639–1645. https://doi.org/10.1101/gr.092759.109 CrossRefPubMedPubMedCentral

23.

da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44–57. https://doi.org/10.1038/nprot.2008.211 CrossRef

24.

Wang M, Zhao Y, Zhang B (2015) Efficient test and visualization of multi-set intersections. Sci Rep 5:16923. https://doi.org/10.1038/srep16923 CrossRefPubMedPubMedCentral

25.

Plaisier CL, Pan M, Baliga NS (2012) A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res 22(11):2302–2314. https://doi.org/10.1101/gr.133991.111 CrossRefPubMedPubMedCentral

26.

Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR (2004) A census of human cancer genes. Nat Rev Cancer 4(3):177–183. https://doi.org/10.1038/nrc1299 CrossRefPubMedPubMedCentral

27.

Di Leva G, Garofalo M, Croce CM (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287–314. https://doi.org/10.1146/annurev-pathol-012513-104715 CrossRefPubMed

28.

Yang SX, Polley E, Lipkowitz S (2016) New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev 45:87–96. https://doi.org/10.1016/j.ctrv.2016.03.004 CrossRefPubMed

29.

Nikitovic D, Kouvidi K, Voudouri K, Berdiaki A, Karousou E, Passi A, Tzanakakis GN (2014) The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans. Biomed Res Int 2014:124321. https://doi.org/10.1155/2014/124321 CrossRefPubMedPubMedCentral

30.

Yang L, Hou Y, Yuan J, Tang S, Zhang H, Zhu Q, Du YE, Zhou M, Wen S, Xu L, Tang X, Cui X, Liu M (2015) Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways. Oncotarget 6(28):25755–25769. https://doi.org/10.18632/oncotarget.4697 PubMedPubMedCentral

31.

Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, Ikejima T (2007) P53-mediated cell cycle arrest and apoptosis through a caspase-3-independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin 28(7):1057–1066. https://doi.org/10.1111/j.1745-7254.2007.00588.x CrossRefPubMed

32.

Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4(2):70–76CrossRefPubMedPubMedCentral

33.

Shan M, Zhang X, Liu X, Qin Y, Liu T, Liu Y, Wang J, Zhong Z, Zhang Y, Geng J, Pang D (2013) P16 and p53 play distinct roles in different subtypes of breast cancer. PLoS ONE 8(10):e76408. https://doi.org/10.1371/journal.pone.0076408 CrossRefPubMedPubMedCentral

34.

Zhang M, Wu WB, Wang ZW, Wang XH (2017) lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. Eur Rev Med Pharmacol Sci 21(5):1020–1026PubMed

35.

Lo PK, Zhang Y, Wolfson B, Gernapudi R, Yao Y, Duru N, Zhou Q (2016) Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis. Oncotarget 7(40):65067–65089. https://doi.org/10.18632/oncotarget.11364 CrossRefPubMedPubMedCentral

36.

Kim J, Abdelmohsen K, Yang X, De S, Grammatikakis I, Noh JH, Gorospe M (2016) LncRNA OIP5-AS1/cyrano sponges RNA-binding protein HuR. Nucleic Acids Res 44(5):2378–2392. https://doi.org/10.1093/nar/gkw017 CrossRefPubMedPubMedCentral

37.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504. https://doi.org/10.1101/gr.1239303 CrossRefPubMedPubMedCentral

38.

Mallet C, Vittet D, Feige JJ, Bailly S (2006) TGFbeta1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem cells 24(11):2420–2427. https://doi.org/10.1634/stemcells.2005-0494 CrossRefPubMed

39.

O’Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, Chesney J, Clem BF (2016) Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res Treat 160(1):29–40. https://doi.org/10.1007/s10549-016-3968-8 CrossRefPubMed

40.

Mirzania M, Safaee SR, Shahi F, Jahanzad I, Zahedi G, Mehdizadeh R (2017) Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer: a report from cancer institute of Iran. Int J Hematol Oncol Stem Cell Res 11(1):37–42PubMedPubMedCentral

41.

Cerase A, Pintacuda G, Tattermusch A, Avner P (2015) Xist localization and function: new insights from multiple levels. Genome Biol 16:166. https://doi.org/10.1186/s13059-015-0733-y CrossRefPubMedPubMedCentral

42.

Matsui M, Corey DR (2017) Non-coding RNAs as drug targets. Nat Rev Drug Discov 16(3):167–179. https://doi.org/10.1038/nrd.2016.117 CrossRefPubMed

43.

Liu E, Liu Z, Zhou Y (2015) Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol 8(4):3803–3810PubMedPubMedCentral

44.

Brockdorff N, Ashworth A, Kay GF, Cooper P, Smith S, McCabe VM, Norris DP, Penny GD, Patel D, Rastan S (1991) Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. Nature 351(6324):329–331. https://doi.org/10.1038/351329a0 CrossRefPubMed

45.

Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9(2):121–132. https://doi.org/10.1016/j.ccr.2006.01.013 CrossRefPubMed

46.

Zhou X, Liu J, Wang W (2014) Construction and investigation of breast-cancer-specific ceRNA network based on the mRNA and miRNA expression data. IET Syst Biol 8(3):96–103. https://doi.org/10.1049/iet-syb.2013.0025 CrossRefPubMed

47.

Chen J, Xu J, Li Y, Zhang J, Chen H, Lu J, Wang Z, Zhao X, Xu K, Li Y, Li X, Zhang Y (2017) Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes. Oncotarget 8(6):10171–10184. https://doi.org/10.18632/oncotarget.14361 PubMed

Title: Systematical analysis of lncRNA–mRNA competing endogenous RNA network in breast cancer subtypes
Authors: Shunheng Zhou
Lihong Wang
Qian Yang
Haizhou Liu
Qianqian Meng
Leiming Jiang
Shuyuan Wang
Wei Jiang
Publication date: 01-06-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4678-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy

A comprehensive tool for measuring mammographic density changes over time

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer

Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare Registry

Lymph drainage of the upper limb and mammary region to the axilla: anatomical study in stillborns

Machine learning to parse breast pathology reports in Chinese

Keynote webinar | Spotlight on antibody–drug conjugates in cancer